These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24041364)

  • 41. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Step Closer to Better Research Prioritization? The ISPOR Value of Information Task Force Reports.
    Fleurence RL; Selby JV
    Value Health; 2020 Mar; 23(3):287-288. PubMed ID: 32197721
    [No Abstract]   [Full Text] [Related]  

  • 43. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
    Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
    Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.
    Hauber AB; González JM; Groothuis-Oudshoorn CG; Prior T; Marshall DA; Cunningham C; IJzerman MJ; Bridges JF
    Value Health; 2016 Jun; 19(4):300-15. PubMed ID: 27325321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report.
    Wolowacz SE; Briggs A; Belozeroff V; Clarke P; Doward L; Goeree R; Lloyd A; Norman R
    Value Health; 2016; 19(6):704-719. PubMed ID: 27712695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The challenges of interpreting research for use by practitioners: comments on the latest products from the Task Force on Community Preventive Services.
    Lipsey MW
    Am J Prev Med; 2005 Feb; 28(2 Suppl 1):1-3. PubMed ID: 15698743
    [No Abstract]   [Full Text] [Related]  

  • 52. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
    Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
    Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Thokala P; Morton A; Sir MY; Marshall DA; Tosh J; Padula WV; Ijzerman MJ; Wong PK; Pasupathy KS
    Value Health; 2017 Mar; 20(3):310-319. PubMed ID: 28292475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ISPOR Task Force For Clinical Outcomes Assessment: Clinical Outcome Assessments: Conceptual Foundation-Report of The ISPOR Clinical Outcomes Assessment - Emerging Good Practices For Outcomes Research Task Force.
    Coyne KS; Wyrwich KW
    Value Health; 2015 Sep; 18(6):739-40. PubMed ID: 26409599
    [No Abstract]   [Full Text] [Related]  

  • 58. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
    Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
    Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.
    Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADA task force on workforce models.
    Von Alman DL
    Dent Assist; 2005; 74(3):4-5, 34. PubMed ID: 16035459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.